Advances in DNA immunization against hepatitis C virus infection: Opportunities and challenges

Human Vaccines

Volumn 5, Issue 8, 2009, Pages 568-571

  Alvarez Lajonchere, Liz ^a   Dueñas Carrera, Santiago ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

DNA immunization; HCV; Therapy; Vaccine

Indexed keywords

CHRON VAC C; CIGB 230; CORE PROTEIN; DNA VACCINE; HEPATITIS C VACCINE; INTERFERON; PEPTIDE VACCINE; PLASMID DNA; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CLINICAL EVALUATION; CLINICAL TRIAL; DNA IMMUNIZATION; DOSE RESPONSE; DRUG ANTIGENICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; GENE TRANSFER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRUS LOAD;

CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; VACCINATION; VACCINES, DNA; VIRAL HEPATITIS VACCINES;

EID: 70349542749     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.8.8572     Document Type: Article

References (30)

1. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14:36-44.
2. Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008; 15:2-11.
3. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961-6.
4. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007; 196:1474-82.
5. Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, Sacchelli L, et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006; 44:126-39.
6. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104:6025-30.
7. Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004; 22:3080-6.
8. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134:1385-95.
9. Nevens F, Roskams T, van Vlierberghe H, Horsmans Y, Sprengers D, Elewaut A, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003; 38:1289-96.
10. Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2007; 13:2406-15.
11. Smith HA. Regulation and review of DNA vaccine products. Dev Biol (Basel) 2000; 104:57-62.
12. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 2008; 26:6225-31.
13. Capone S, Zampaglione I, Vitelli A, Pezzanera M, Kierstead L, Burns J, et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 2006; 177:7462-71.
14. Weiner DB. DNA vaccines: crossing a line in the sand. Introduction to special issue. Vaccine 2008; 26:5073-4.
15. Li P, Wan Q, Feng Y, Liu M, Wu J, Chen X, Zhang XL. Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine 2007; 25:1544-51.
16. Shi L, Liu S, Fan GX, Sheng L, Ren HX, Yuan YK. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes. Viral Immunol 2006; 19:702-11.
17. Elliot LN, Lloyd AR, Ziegler JB, Ffrench RA. Protective immunity against hepatitis C virus infection. Immunol Cell Biol 2006; 84:239-49.
18. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184:16-21.
19. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12:190-7.
20. Duenas-Carrera S. DNA vaccination against hepatitis C. Curr Opin Mol Ther 2004; 6:146-50.
21. Park SH, Lee SR, Hyun BH, Kim BM, Sung YC. Codelivery of PEG-IFNalpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. Vaccine 2008; 26:3978-83.
22. Kim JJ, Yang JS, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFNgamma or IL-4 gene adjuvants. Vaccine 2001; 19:2496-505.
23. Arcuri M, Cappelletti M, Zampaglione I, Aurisicchio L, Nicosia A, Ciliberto G, Fattori E. Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination. J Gene Med 2008; 10:1048-54.
24. Chu W, Gong X, Li Z, Takabayashi K, Ouyang H, Chen Y, et al. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell 2000; 103:909-18.
25. Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, Fagrouch Z, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007; 45:602-13.
26. Alvarez-Lajonchere L, Shoukry NH, Gra B, Amador-Canizares Y, Helle F, Bedard N, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2008.
27. Sallberg M, Diepolder H, Jung MC, Frelin L, Mathiesen I, Fons M, et al. Antiviral effects of therapeutic vaccination with naked DNA delivery by in vivo electroporation in patients with chronic hepatitis C. Hepatology 2008; 48:1022-3.
28. Alvarez-Lajonchere L, Gonzalez M, Alvarez-Obregon JC, Guerra I, Vina A, Acosta-Rivero N, et al. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. Biotechnol Appl Biochem 2006; 44:9-17.
29. Yuan TF. Vaccine submission with muscle electroporation. Vaccine 2008; 26:1805-6.
30. Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, McClements WL, et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999; 18:18-28.